Pharmadule Morimatsu has successfully handed over China's First Modular mRNA Coronavirus Vaccine Facility within 7.5 month

Published Friday, September 3, 2021

7.5 months only , half timeline compared to traditional project construction, Pharmadule Morimatsu has successfully handed over China's First Modular mRNA Coronavirus Vaccine Facility to China big vaccine manufacturer, WALVAX. The facility was designed and fabricated according to WHO regulation, and Pharmadule Morimatsu provides "one-stop" solution from basic design, detail design, core equipment fabrication, modular construction, to transportation, on-site installation and commissioning.
 
At the time of on-site civil construction, the modular factory and process system were fabricated and commissioned simultaneously in Pharmadule Morimatsu well-equipped factory in Shanghai, that enabled more than 80% of work to be completed before shipment. Compared with traditional construction, it not only improves the production quality of products and the certainty of project delivery, but also greatly reduces the on-site workload. Finally, the overall delivery time was shortened by more than half compared with traditional projects, which effectively accelerated the industrialized production of the mRNA Coronavirus vaccine in China.
 
Digital technology runs through the whole project life cycle to achieve high efficiency of project implementation and lean plant operation & maintenance.
 
Pharmadule Morimatsu's one-stop solution empowered by modularization and digitization promotes the industrialized production of mRNA coronavirus vaccine.

Watch more

 

mRNA-CN

Back to news
Pharmadule Morimatsu AB  |   DanvikCenter 28  |   SE - 131 30 Nacka  Sweden  |   Phone: +46 (0)8 587 42 000  |   Email: info@pharmadule.com